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ABSTRACT
Introduction: We are undertaking a randomised
controlled trial (fAmily led rehabiliTaTion aftEr stroke in
INDia, ATTEND) evaluating training a family carer to
enable maximal rehabilitation of patients with stroke-
related disability; as a potentially affordable, culturally
acceptable and effective intervention for use in India.
A process evaluation is needed to understand how and
why this complex intervention may be effective, and to
capture important barriers and facilitators to its
implementation. We describe the protocol for our
process evaluation to encourage the development of
in-process evaluation methodology and transparency in
reporting.
Methods and analysis: The realist and RE-AIM
(Reach, Effectiveness, Adoption, Implementation and
Maintenance) frameworks informed the design. Mixed
methods include semistructured interviews with health
providers, patients and their carers, analysis of
quantitative process data describing fidelity and dose
of intervention, observations of trial set up and
implementation, and the analysis of the cost data from
the patients and their families perspective and
programme budgets. These qualitative and quantitative
data will be analysed iteratively prior to knowing the
quantitative outcomes of the trial, and then triangulated
with the results from the primary outcome evaluation.
Ethics and dissemination: The process evaluation
has received ethical approval for all sites in India. In
low-income and middle-income countries, the available
human capital can form an approach to reducing the
evidence practice gap, compared with the high cost
alternatives available in established market economies.
This process evaluation will provide insights into how
such a programme can be implemented in practice and
brought to scale. Through local stakeholder
engagement and dissemination of findings globally we
hope to build on patient-centred, cost-effective and
sustainable models of stroke rehabilitation.
Trial registration number: CTRI/2013/04/003557.
INTRODUCTION
With a rapidly rising global burden of
disease attributed to non-communicable dis-
eases, access to high-quality evidence-based
Strengths and limitations of this study
▪ A strength of our study protocol includes the use
of implementation theories, quantitative and
qualitative research methods and our iterative
approach to analysis.
▪ Consideration of costs to the patient is vital to
assess whether a programme would be afford-
able outside a trial setting, which is often inad-
equately reported in trials. The design of this
process evaluation allowing the triangulation of
within-trial cost data and qualitative data will add
to the limited current evidence regarding the
socioeconomic burden of stroke to patients and
their families in India.
▪ Limitations to our current approach include the
overlap between the trial coordinating team and
the process evaluation team. While a strength of
this approach is that the team members have an
in-depth knowledge of the trial and its imple-
mentation, a challenge for the process evaluation
is for team members to be aware of their own
biases in the conduct of the interviews for posi-
tive findings towards the trial.
▪ Our sampling approach for the interviews has
been designed to maximise variation which
should increase our understanding of the differ-
ing contextual factors. Pragmatically this is only
a small sample (about 100 participants) of a
1200 patient trial. However, this is a large
sample for qualitative research, and other data
sources such as observations, administratively
collected data and relevant policies would be
reviewed to provide additional context.
Liu H, et al. BMJ Open 2016;6:e012027. doi:10.1136/bmjopen-2016-012027 1
Open Access Protocol
healthcare is essential. Complex interventions, deﬁned
as interventions with multiple interacting components,
are frequently deployed in an attempt to address health
system deﬁciencies experienced by patients and provi-
ders.1 Process evaluations, which are typically carried out
for trials of complex interventions, can help explain for
whom, how and why the intervention had a particular
impact.2 Such evaluations address the question ‘Is this
intervention acceptable, effective and feasible (for me
or) for this population?’3 Gaining a clear understanding
of the causal mechanisms of complex interventions is
vital in being able to scale up or deliver an effective
intervention in other settings.
This is especially relevant for the randomised con-
trolled trial known as the fAmily led rehabiliTaTion
aftEr stroke in INDia (ATTEND), which is being con-
ducted at 14 hospitals in India—across populations with
differing languages, cultures and health systems.4–6 The
annual incidence of stroke in India is estimated to be
152–262 cases per 100 000 population, with prevalence
of 0.47–0.54%.7 This means that there is a signiﬁcant
burden on society due to stroke disability with limited
stroke units isolated to urban areas and limited rehabili-
tation services.8 Table 1 highlights some socioeconomic
health indicators and available stroke incidence data in
different states where our sites are based.
The ATTEND intervention has multiple interacting
components. We developed an evidence-based rehabili-
tation intervention package consisting of providing infor-
mation on stroke, identiﬁcation and management of low
mood, importance of repeated practice of speciﬁc activ-
ities, task-oriented training, early supported discharge
planning and joint goal setting with the patient and
nominated family. Physiotherapists employed for the
trial are trained in this evidence-based rehabilitation
intervention package.6 These physiotherapists (known as
stroke coordinators in the trial) provide support to the
patient and family within the hospital and in subsequent
home visits, with the aim of training a nominated carer
and in enabling optimal rehabilitation of the patient. As
such, a careful consideration of the contextual patient
factors, such as health literacy, access to care and ﬁnan-
cial considerations, is needed.9–11 The context of each
patient can have an impact on the behaviour of the
carer and the patient, which will affect patient improve-
ment in disability and dependence outcomes as mea-
sured by the modiﬁed Rankin scale (mRS) and other
outcome measures (see ﬁgure 1).6 Thus, the process
evaluation could help explore reasons for any variations
in trial effectiveness, and address questions about the
generalisability of this intervention across different set-
tings. A deeper appreciation of the needs of patients
poststroke and their families will be valuable for health
system and policy reform in India.4
A key role of our process evaluation would be to
inform how the intervention can be implemented into
practice and policy, if proven effective. It is well recog-
nised that the generation of good quality evidence does
not always translate into improved patient health out-
comes.12 Financial barriers, such as high out of pocket
costs for diagnostic imaging or provision of treatment,
are possible reasons for an intervention not being deliv-
ered once shown to be efﬁcacious in a trial.13–16 Such
costs are likely to frame the ﬁnancial incentives of differ-
ent players within the system and explain behaviour that
is potentially at odds with the idealised operation of an
Table 1 Sociodemographic health indicators across the participating ATTEND sites
City/state of
participating sites
Life expectancy at
birth (2002–2006)*
(years)
Poverty level
(2004–2005)*
(%)
Per capita health
expenditure (in Rs)*
Age-standardised incidence rate for
stroke† (from population stroke
epidemiology studies)
Ludhiana, Punjab 69.4 8.4 1359 Not available
New Delhi, Delhi Not available Not available Not available Not available
Kochi and
Trivandrum, Kerala
74 15 2950 135/100 000 person-years
Guntur, Andhra
Pradesh
64.4 15.8 1061 Not available
Chennai and Vellore,
Tamil Nadu
66.2 22.5 1256 Not available
Kolkata, West
Bengal
64.9 24.7 1259 145/100 000 person-years
Tezpur, Assam Not available 19.7 774 Not available
Hyderabad, Andhra
Pradesh
64.4 15.8 1061 Not available
Bangalore,
Karnataka
65.3 25 830 Not available
INDIA 63.5 27.5 1201 119–145 per 100 000 person-years
*Ministry of Health and Family Welfare, Government of India. Annual report to the People on Health. December 2011.
†Pandian J, Suhan P. Stroke Epidemiology and stroke care services in India. J Stroke 2013;15(3):128–134.
ATTEND, fAmily led rehabiliTaTion aftEr stroke in INDia.
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intervention. Understanding these cost barriers can
inform how remuneration and payment systems may be
shaped to facilitate implementation beyond a trial
setting.14 Incorporating an assessment of stakeholders’
perceptions of how an intervention can be practically
funded, delivered and scaled up is crucial.
Process evaluations can also add to the literature of
how collaborations between stakeholders (ie, health
providers, academics, policymakers, patients, carers)
may facilitate research translation.17 Understanding
how and why an international collaboration of stroke
experts came together to design and implement a feas-
ible, locally adapted large-scale trial in India would also
be helpful for future research. Lessons learnt from this
trial, which is funded by the National Health and
Medical Research Council (NHMRC) of Australia, with
capacity building objectives in India, would be valuable
in informing future international collaborative
research.
The UK Medical Research Council (MRC) recom-
mends publishing a protocol for a process evaluation so
as to promote development of methodology and trans-
parency in the reporting of the ﬁndings. In this proto-
col, we outline our aims, methods and study design. The
core aims of this process evaluation are: (1) to explore if
the ATTEND trial was delivered as intended (eg, ﬁdelity and
dose); (2) to understand whether, how and why the intervention
had an impact, through exploring providers’, patients’ and
carers’ perspectives of their usual care and of the intervention;
(3) and to explore if the results are likely to be generalisable,
scalable and sustainable through exploring stakeholders’ (hos-
pital stroke unit staff, providers, patients and carers) experiences
of the intervention and its perceived impact. This would
include an evaluation of costs from the societal perspective,
including the health system and also for the patients and fam-
ilies. Finally, (4) we aim to explore implementation barriers and
facilitators of a complex intervention by an international
collaboration.
Figure 1 The ATTEND RCT
flow chart. This highlights the
outcome measures used and the
study visits. ADL, activities of
daily living; ATTEND, fAmily led
rehabiliTaTion aftEr stroke in
INDia; EQ-5D-3L, EuroQol
5-Dimensional, 3 Levels; NIHSS,
National Institutes of Health
Stroke Scale; RCT, randomised
controlled trial; WHOQOL-BREF,
WHO Quality of Life (Brief ).
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METHODS AND ANALYSIS
Theoretical frameworks informing this process evaluation
Two theoretical frameworks with emphasis on translating
evidence in the real-world setting were used to inform
our methods.
The ﬁrst was the RE-AIM (Reach, Effectiveness,
Adoption, Implementation and Maintenance) frame-
work. It has been used by researchers in the develop-
ment, evaluation and dissemination of research, using
qualitative and quantitative methods.18 The framework’s
ﬁve domains highlight the need to look into the propor-
tion and representativeness of the participants involved
in the intervention, the impact of the intervention, the
ﬁdelity of trial implementation and at how a programme
may be institutionalised into organisational practice after
the conclusion of the trial. Thus, pending ATTEND’s
results, and resources permitting, there may be scope
for a post-trial evaluation to explore how and why there
were changes in practice and policy.19
The second framework that informed our methods
was the Realist framework (Context, Mechanism,
Outcomes).20 It has been successfully used in process
evaluations as a theoretical basis for identifying potential
causal mechanisms for how an intervention works for
whom, under what contexts and therefore fosters uptake
of research-based knowledge into practice.21 22 Given
the complexity of the ATTEND trial from contextual
macrolevel factors, such as different socioeconomic
demographics, cultural differences, health system
funding structures at each state, to microlevel factors
such as literacy of patients and carers; the realist frame-
work would be valuable in framing our analysis in under-
standing the mechanism within the ‘black box’ of the
intervention.23
Our process evaluation framework and the hypothesised
causal mechanisms of ATTEND
The framework (ﬁgure 2) highlights the key questions
for the process evaluation, incorporating the above the-
ories and our work plan. We have brieﬂy outlined our
hypothesised causal mechanisms of ATTEND’s complex
intervention within the framework as per the MRC’s
guidance on process evaluations.19 The framework is
divided into sections of context, implementation of the
trial, mechanisms of the trial and outcomes of the trial
with the ﬁnal objective of reducing the burden of stroke
through a sustainable model of care.
Mixed methods used to address the aims of the process
evaluation
1. To explore if the trial was delivered as intended (eg,
ﬁdelity and dose)
Figure 2 The ATTEND process evaluation framework. The process evaluation components are highlighted in blue boxes—
exploring contextual factors, the implementation of the ATTEND trial, mechanisms of impact from the intervention. Questions
informed by the RE-AIM and Realist framework fit within these components. These components are informed by the causal
assumptions of ATTEND intervention and will inform the interpretation of the primary and secondary outcomes. ATTEND, fAmily
led rehabiliTaTion aftEr stroke in INDia; RE-AIM, Reach, Effectiveness, Adoption, Implementation and Maintenance.
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This will be achieved through an analysis of the adminis-
tratively collected process data (eg, competency mea-
sures, frequency of training), electronic case record ﬁle,
quantitative data and activity logs (eg, the measurement
of the total time spent per patient in both arms of the
trial with the usual care physiotherapist, the number of
meetings and time spent with each family caregiver by
the stroke coordinator during their inpatient stay and
after discharge). If the analysis provides any evidence of
variation between the active and control groups in terms
of amount of time spent on different tasks, we will inves-
tigate and provide further training if required.
2. To understand whether, how and why the interven-
tion had an impact through exploring the providers’,
patients’ and carers’ perspectives of usual care and of
the intervention
▸ Non-participant observations of all the sites to
understand the contextual factors at each site,
which may help explain variations in outcomes.
Our observation template has been adapted from
a process evaluation of a similar intervention24
and includes issues on trial set up, trial implemen-
tation and impact. See online supplementary add-
itional ﬁle 1 for a copy of the template.
▸ Semistructured in-depth interviews will be con-
ducted with patients, carers, stroke coordinators
and the stroke unit staff of hospitals to understand
their perspectives of the causal mechanisms of the
intervention and to seek their suggestions on how
the intervention could be scaled up or rolled out.
Methods for our qualitative interviews have been
described as per the consolidated criteria for
qualitative research:25
A. Research team and reﬂexivity: The research team is
multidisciplinary and comprises of the trial’s chief
investigators, the clinical trial coordinating staff and
research fellows from India, UK and Australia. The
team has background in medicine, physiotherapy,
health economics, pharmaceutical trials and public
health; with varied experience in qualitative research.
In particular, three of the team members (HL, MA
and SJ) have training in qualitative methods. HL who
coordinated the team, organised face-to-face qualita-
tive workshops to train the rest of the team prior to
the conduct of interviews and will take a leading role
in analyses. A team of six people will conduct the
interviews. The team members, who are part of the
clinical trial management team, have a good under-
standing of the trial and are known to the principal
investigators, stroke coordinators and blinded asses-
sors but will not have established relationships with
the patients and their carers.
Semistructured interview guidelines based on our study
objectives have been developed and pilot tested. The key
areas covered include overall views of the health and
socioeconomic impact of stroke on patients and families,
stroke management in India, acceptability of the
family-led rehabilitation intervention, the general
healthcare experience of patients and their families and
translation of the intervention into practice and policy.
Early ﬁndings will be discussed with the study team, and
minor changes made to the interview guidelines if
needed. (See online supplementary additional ﬁles 2–4
for the interview guidelines for the health provider,
carer and patient, respectively.)
B. Study design: Sampling: Participants for the interviews
will be recruited using maximum variation purposive
sampling. Variables to be considered for patients and
carers are: usual care versus intervention arm,
primary outcome (as measured by the mRS at 6
months), gender and the region of India they are
from. Variables to be considered for stroke unit
providers: healthcare roles (ie, neurologists, phy-
siotherapists, nurses and the stroke coordinators),
private versus public government hospitals and the
region of India the hospitals are located.
A list of patients and caregivers who match our sam-
pling criteria will be generated. They will be contacted
by the local site staff (either the stroke coordinator or
the ‘blinded assessor’) and where relevant, reasons for
not participating will be elicited. They will be formally
consented by the interviewer face-to-face. Interviews with
carers and patients will be conducted either individually
or with both together either at the participant’s home
or at the hospital. These interviews will be conducted in
local languages and the services of an interpreter may
be required. The beneﬁts of interviewing the patient
and carer separately would be to gather perspectives
which otherwise may not be shared should the other be
present. Healthcare providers will be invited to partici-
pate in interviews either by a letter or in person by the
clinical coordinating team during their site visits, and
conducted in English. Written informed consent (see
online supplementary additional ﬁle 5 for a copy of the
form) will be obtained from all interviewed participants.
As per qualitative research methods,26 analysis is iterative
and thus the interviewer will carry out preliminary the-
matic data analysis at the end of each interview and
discuss any highlights with the rest of the interview
team. For example, the ﬁndings from the pilot inter-
views were discussed during the qualitative workshop, in
order for the team of interviewers to explore emerging
themes in subsequent interviews. It is estimated that at
least ﬁve sites would be sampled, with 3–4 health provi-
ders and about 4–6 patient/carer dyads interviewed from
each site. According to the sampling matrix, we will inter-
view equal numbers from both usual care versus interven-
tion arm, and also include sampling for gender. For
example, at each site, two usual care dyads and two inter-
vention group dyads will be invited to participate.
In addition, some of the stroke coordinators and the
independent assessors at the other sites will be inter-
viewed. That is, an estimated 80–100 interviews will be
conducted though the ﬁnal numbers will be determined
by saturation of themes and resources permitting.
Interviews will be conducted face-to-face, audio recorded
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and professionally translated and transcribed verbatim.
These will be uploaded into a software program NVivo
V.9 (QSR International, Melbourne, Victoria, Australia)
to assist with data management.
3. To explore if the results are generalisable, scalable
and sustainable through exploring health providers’,
patients’ and carers’ experiences of the intervention
and its perceived impact. This will include an evalu-
ation of costs from the societal perspective including
the health system, and for patients and their families.
(note this is separate to the formal cost-effectiveness
study which has been set out in the original trial
protocol)6
▸ One of the key domains in the semistructured
interviews will be exploring participants’ perspec-
tives of what they expect post-trial in relation to this
intervention. The ﬁndings related to these ques-
tions will address this aim.
▸ Cost components of the intervention which will be
relevant to implementation outside a trial setting
will be considered. This will be extracted from the
programme budget and trial contracts and
includes, for example, costs of employment of a
physiotherapist to implement the intervention,
travel costs of the home visits and costs of any edu-
cational material required as part of the interven-
tion. Relevant questions asked by the blinded
assessor at the 3-month and 6-month follow-up
visits include loss of family income (eg, number of
hours of work taken off) due to carer’s additional
responsibility and medical costs. (Participants are
encouraged to keep receipts of related medical
costs.)
4 To explore implementation barriers and facilitators
of a complex intervention by an international
collaboration.
A research fellow not involved in the implementation
of the trial will conduct focus group interviews and
semistructured interviews with members of the clinical
trial coordinating team and also with the trial investiga-
tors in regards to perceived barriers and facilitators
to trial implementation. Findings from these interviews
in addition to relevant ﬁndings from the interviews
with the health providers, patients and carers will
inform lessons learnt from this trial for future research
collaborations.
Analysis plan for the process evaluation
Thematic analysis will be used for the qualitative analysis
to code closely to the data and establish themes within
the subheadings of the process evaluation framework
(ﬁgure 2).26 Constant iterative comparison between
sources, for example, patient, carer and health provider
will be carried out in order to identify common, as well
as distinctive, themes.26 Contextual information from
observations, other process data and costs to patients
and families will be used to triangulate the emerging
themes.27 The quantitative process data will help inform
ﬁdelity and the time logs of the stroke coordinator will
provide descriptive data on dose. Fidelity data will be
reviewed at six monthly intervals.
The process evaluation framework (ﬁgure 2) will aid
in the analysis by triangulating the process’s quantitative
data with the relevant qualitative data addressing the
questions within its subheadings.27 For example, under
the heading ‘implementation—ﬁdelity and dose’, a spe-
ciﬁc question would be whether usual care is provided
equally in both arms of the intervention, and thus the
quantitative process data would be the time spent by the
usual care physiotherapist and should be almost equiva-
lent in both arms documented in the logs (or not), and
the qualitative data would include, for example, the
usual care physiotherapists’ responses as to whether they
did treat all the patients equally, or the neurologist’s
description of what happens to the study participants.
Other forms of triangulation to increase the reliability
of our results include the sampling of different perspec-
tives, that is, patient, carer, neurologists and stroke coor-
dinators and also through the triangulation of different
analysts in the team who bring their own cultural back-
grounds, academic experience (eg, rehabilitation medi-
cine, pharmacy, physiotherapy) and knowledge about
different aspects of the trial into the analysis.26
In line with the MRC guidelines, the process evalu-
ation data should be analysed prior to knowing the trial
outcomes, ﬁrst to remove bias, though there is a role for
post hoc exploration of reasons for trial outcomes.2
First, we will analyse our process evaluation data itera-
tively on an ongoing basis. If there are any process issues
which would impact on trial integrity that need to be
addressed, these will be fed back through the usual man-
agement communication channels.28
The framework serves as a template to consolidate the
ﬁndings, and will be a dynamic structure with changes to
be made if required. This means that our understanding
of the causal mechanisms of the intervention may change
with the iterative analysis of the process evaluation data.
There will also be a post hoc examination of the
process evaluation ﬁndings, in light of the main results
of the trial.29 For example, in our experience, our
assumption is that early supported discharge, as part of
the intervention, will decrease costs to the system and
family, enable early patient rehabilitation which may
improve patient recovery (primary outcome) and result
in shorter hospital stays in the intervention arm.
However, in piloting our observation template at one
site, we discovered that there was shortage of beds such
that at that government hospital patients were dis-
charged at the earliest possibility, for example, when
they were medically stable. This may perhaps be different
to developed country settings, such as UK, and ultimately
may explain potential divergences in the ﬁndings of this
study to that of a recent meta-analyses of rehabilitation
trials (which showed positive results of early supported dis-
charge).30 31 A major consideration in the process evalua-
tion therefore may be regarding the length of stay in
6 Liu H, et al. BMJ Open 2016;6:e012027. doi:10.1136/bmjopen-2016-012027
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hospital. The examination of such secondary outcomes
and contextual ﬁndings from the process evaluation is an
example of how we could gain a deeper understanding of
the assumed causal mechanisms of the ATTEND interven-
tion (as depicted in the logic model in the overall process
evaluation framework). Such insights will help inform the
ﬁnal logic model of how the intervention truly impacted
the trial effectiveness outcomes, and inform the generalis-
ability of the intervention.
ETHICS AND DISSEMINATION
Ethics
Ethical approval for the trial and process evaluation has
been obtained from Research Integrity, the Human
Research Ethics Committee at the University of Sydney
and at each local site. See online supplementary add-
itional ﬁle 6 for the details of ethic committees at the
local sites.
The ethical implications of this scope of research
include the considerations of NHMRC ethical guidelines
such as research merit and integrity, beneﬁcence and
respect in relation to qualitative methods.32
Dissemination
Our process evaluation aims to complement a robust
blinded outcome evaluation of the trial end points and
inform our stakeholders how, for whom and why this
model of family led rehabilitation could have an impact.
This is especially relevant for India which is in ‘epi-
demiological transition’ with a diverse sociodemographic
proﬁle, and an increasing burden from non-
communicable diseases which could result in greater
health inequity.4 16 A stated aim in India’s key national
strategy for non-communicable diseases is to increase
access to healthcare to 80% with costs not being a key
barrier. Strategies such as the family-led rehabilitation
programme, which marshal family and community
resources in the care of patients with chronic conditions
will, by ﬁnancial necessity, play a greater role in the
future. In low-income and middle-income countries, the
available human capital can form one approach to redu-
cing the evidence practice gap, compared with the high
cost alternatives available in established market econ-
omies. This process evaluation will provide insights into
how such a programme can be implemented in practice
and brought to scale.
The Indian Institute of Public Health has been allo-
cated resources for the dissemination of results through
the engagement of local policymakers and health practi-
tioners. Apart from stakeholder engagement, dissemin-
ation of our ﬁndings globally will be accomplished
through publishing our results in relevant journals and
conferences to build on the literature in providing
affordable, holistic and accessible stroke rehabilitation
models of care.
We describe our protocol to encourage development
in process evaluation methodology, transparency in
reporting and to build on this emerging area of health
services research which is much needed in addressing
the complicated global health needs through sustain-
able, patient-centred and evidence-based complex
interventions.
Trial status
In regards to the ATTEND trial, the ﬁrst patient was
randomised on 13 January 2014 and the recruitment
surpassed the sample size of 1200 in January 2016. The
ATTEND process evaluation, started in March 2015
with the observational visits of the sites and the ﬁdelity
and dose quantitative data have been reviewed in six
monthly intervals since March 2015, pilot interviews
were conducted with health providers in July 2015 and
completion of the patient, carer and health provider
interviews is expected by May 2016, with ongoing prelim-
inary and iterative analysis.
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